These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2716953)

  • 1. Response of a GH- and TSH-secreting pituitary adenoma to a somatostatin analogue (SMS 201-995): evidence that GH and TSH coexist in the same cell and secretory granules.
    Malarkey WB; Kovacs K; O'Dorisio TM
    Neuroendocrinology; 1989 Mar; 49(3):267-74. PubMed ID: 2716953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a long-acting somatostatin analogue (SMS 201-995) on a growth hormone and thyroid stimulating hormone-producing pituitary tumor.
    Hirasawa R; Hashimoto K; Makino S; Suemaru S; Takao T; Ota Z; Hoshida Y; Yoshino T; Akagi T
    Acta Med Okayama; 1991 Apr; 45(2):107-15. PubMed ID: 1867112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
    Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P
    J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: evidence for secretion of TSH with increased bioactivity.
    Beck-Peccoz P; Piscitelli G; Amr S; Ballabio M; Bassetti M; Giannattasio G; Spada A; Nissim M; Weintraub BD; Faglia G
    J Clin Endocrinol Metab; 1986 Apr; 62(4):704-11. PubMed ID: 2419356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine and immunohistochemical studies on thyrotropin (TSH)-secreting pituitary adenomas: responses of TSH, alpha-subunit, and growth hormone to hypothalamic releasing hormones and their distribution in adenoma cells.
    Kuzuya N; Inoue K; Ishibashi M; Murayama Y; Koide Y; Ito K; Yamaji T; Yamashita K
    J Clin Endocrinol Metab; 1990 Nov; 71(5):1103-11. PubMed ID: 1699960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human TSH-secreting adenoma: endocrine, biochemical and morphological studies. Evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201-995 treatment.
    Polak M; Bertherat J; Li JY; Kujas M; Le Dafniet M; Weizani H; Van Effenterre R; Epelbaum J; Turpin G
    Acta Endocrinol (Copenh); 1991 Apr; 124(4):479-86. PubMed ID: 1851593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TSH secretion in the human pituitary adenomas.
    Trouillas J; Girod C; Loras B; Claustrat B; Sassolas G; Perrin G; Buonaguidi R
    Pathol Res Pract; 1988 Sep; 183(5):596-600. PubMed ID: 3237550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A; Sanno N; Tahara S; Osamura YR
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone.
    Hofland LJ; van Koetsveld PM; van Vroonhoven CC; Stefanko SZ; Lamberts SW
    J Clin Endocrinol Metab; 1989 Mar; 68(3):613-20. PubMed ID: 2493040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma.
    George SR; Kovacs K; Asa SL; Horvath E; Cross EG; Burrow GN
    Clin Endocrinol (Oxf); 1987 Apr; 26(4):395-405. PubMed ID: 2888549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
    Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
    J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
    Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
    J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
    Iglesias P; Díez JJ
    J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Sy RA; Bernstein R; Chynn KY; Kourides IA
    J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
    Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.